MoonLake Announces Long-term Week 40 Results of VELA-1 and VELA-2 Trials
MoonLake Immunotherapeutics announces long-term Week 40 results of the Phase 3 VELA-1 and VELA-2 clinical trials of its registrational global program in patients with moderate-to-severe HS and confirms the presentation of the data at the 2026 American Academy of Dermatology, AAD, Annual Meeting later. The Phase 3 VELA program in adults with moderate-to-severe HS used the higher clinical response level of HS Clinical Response 75 as the primary endpoint, which defines a response as an at least 75% reduction in abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count. Key secondary endpoints included the change from baseline in the HS Quality of Life score as well as other scores that reflect the evolving needs of HS patients, treating physicians and regulators. These included the percentage of participants achieving at least a 55% reduction in the International HS Severity Scoring System, the percentage of participants achieving at least a 3-point improvement from baseline in the worst skin pain Numerical Rating Scale among participants with a baseline score of at least 3 points, and the percentage of patients achieving a Dermatology Quality of Life Index total score improvement of greater than or equal to4, among participants with a baseline DLQI greater than or equal to4. A total of 838 patients were enrolled across both trials. Following the primary endpoint at Week 16, patients in the placebo arm were switched to receive SLK treatment for the remaining duration of the trial until Week 52. Patients originally randomized to the SLK arm continued to receive SLK at the monthly 120mg maintenance dose. All patients have completed Week 40 and discontinuation rates were at the low end to those observed in other pivotal HS trials. After Week 52, patients have the opportunity to switch into a two-year open-label extension trial.
Trade with 70% Backtested Accuracy
Analyst Views on MLTX
About MLTX
About the author
BVF Partners Sells $62.96 Million in MoonLake Immunotherapeutics Shares
- Transaction Overview: On April 2, 2026, BVF Partners L.P. directly sold 3,750,000 shares of common stock for approximately $62.96 million, indicating ongoing interest in MoonLake Immunotherapeutics despite the sale.
- Historical Comparison: This transaction marks the largest direct sale reported by BVF in the SEC database, surpassing the previous sale of 2,000,000 shares, suggesting a strategic adjustment in their investment approach towards MoonLake.
- Holding Analysis: Post-transaction, BVF retains 15.9 million shares and an additional 25,667 shares via unexercised options, indicating a willingness to participate in future price appreciation, even after trimming its holdings.
- Investor Outlook: Although BVF reduced its stake by 19%, it still represents 8.76% of its total AUM, reflecting continued confidence in MoonLake's long-term growth potential, particularly with its proprietary Nanobody technology targeting significant unmet medical needs.
BVF Sells 3.75 Million Shares of MoonLake Immunotherapeutics
- Sale Overview: On April 2, 2026, BVF Partners L.P. sold 3.75 million shares of MoonLake Immunotherapeutics for approximately $62.96 million, reducing its direct holdings to 1,039,238 shares, which represents a 78.30% decrease in ownership.
- Ownership Change: This transaction accounted for 78.30% of BVF's direct stake in MoonLake, indicating a strategic reduction in exposure to biotechnology investments rather than a complete exit, reflecting a cautious approach to market volatility.
- Company Strategy and Outlook: MoonLake focuses on leveraging its proprietary Nanobody technology to develop innovative therapies for inflammatory diseases, and despite BVF's sale, the company continues to advance its pipeline targeting dermatological and rheumatological conditions, suggesting potential for long-term growth.
- Market Reaction and Investment Advice: Although MoonLake's shares have rebounded sharply since the beginning of the year, the high volatility in the biotechnology sector necessitates caution from investors; BVF's sale appears more as a portfolio rebalancing move rather than a negative outlook on the company's future prospects.
MoonLake's Clinical Trial Results Spark Interest
- Clinical Trial Results: MoonLake recently announced that in its late-stage trials, 62% of patients treated with sonelokimab achieved a 75% reduction in abscess and inflammatory nodule count, setting a new standard for long-term control of HS, surpassing existing FDA-approved drugs.
- Positive Market Reaction: Following the clinical data release, MoonLake's stock garnered significant retail interest on Stocktwits, with sentiment remaining in the 'extremely bullish' territory, indicating strong confidence in the company's future performance.
- Optimistic Analyst Ratings: According to Koyfin, 12 out of 16 analysts covering MLTX rated it 'Buy' or higher, with an average 12-month price target of $26.71, suggesting a potential upside of about 41%, reflecting market expectations for long-term growth.
- Acquisition Rumors Resurface: Despite Merck's failed attempt to acquire MoonLake for over $3 billion, optimism regarding potential future buyouts remains strong among investors, driven by interest in recent mergers in the biopharma sector, which could further boost the stock price.
MoonLake Immunotherapeutics Phase 3 Trial Results Show Promising Outcomes
- Sustained Clinical Improvement: In the Phase 3 VELA trials, 62% of patients achieved HiSCR75 by Week 40, indicating significant clinical responses and reinforcing Sonelokimab's potential for long-term disease control, addressing a critical unmet need for patients and physicians.
- Quality of Life Enhancement: Patients experienced an average HiSQOL score improvement of 12 points, with most transitioning from 'very severe' to 'mild/none', which not only enhances patient quality of life but also provides a positive outlook for future treatment options.
- Significant Pain Relief: Up to 43% of patients achieved at least a 3-point improvement in worst skin pain, demonstrating Sonelokimab's effectiveness in alleviating patient suffering, potentially attracting more patients for subsequent treatments.
- Good Safety Profile: No new safety signals were observed throughout the trials, and discontinuation rates remained low, establishing a solid foundation for Sonelokimab's market launch and future BLA submission.
Escalating Middle East Tensions Impact Markets
- Escalating Middle East Conflict: The conflict in the Middle East has entered its fifth week with the involvement of Houthi militants and the deployment of 3,500 additional U.S. troops, raising fears of broader escalation, which has led the Dow to enter correction territory and the S&P 500 to post its fifth consecutive weekly decline, indicating cautious investor sentiment.
- Oil Price Surge Risk: Brent crude prices surged above $116 in early Monday trading, with analysts warning that if the conflict extends through June, oil could reach $200 per barrel, highlighting the potential threat to global energy supplies stemming from the escalating tensions in the region.
- Market Reaction: Despite President Trump's extension of the deadline for potential strikes on Iran's energy infrastructure, investor sentiment remains cautious, resulting in S&P 500 and Nasdaq 100 futures declining by 0.6% and 0.7% respectively, reflecting the market's heightened sensitivity to geopolitical risks.
- Gold Market Turmoil: Global long-term bonds experienced $4.7 billion in weekly outflows, while gold prices approached $4,490, indicating a rising demand for safe-haven assets, with 95% of stocks in the VanEck Gold Miners ETF now in a bear market, reflecting market uncertainty and investor risk aversion.
MLTX Stock Soars After Positive Phase 3 Results for Lead Skin Disease Treatment, Most Patients Show Improvement
Treatment Efficacy: Recent data from the Week-40 Phase 3 trials indicate that 62% of patients treated with Sonelokimab for hidradenitis suppurativa showed significant improvement after 40 weeks, with up to 32% achieving near-complete lesion clearance.
Patient Outcomes: Patients reported reductions in pain and improvements in daily functioning, with 65% experiencing overall quality of life enhancements and 43% noting a clear reduction in their worst skin pain.
Market Response: Shares of Moon Lake Immunotherapeutics (MLTX) rose over 6% following the positive trial results, reflecting strong investor sentiment and expectations for continued clinical benefits.
Future Developments: The company is preparing for upcoming trials and potential regulatory submissions, with a focus on expanding its treatment options and maintaining a consistent safety profile as indicated by previous studies.
BVF Partners Sells $62.96 Million in MoonLake Immunotherapeutics Shares
- Transaction Overview: On April 2, 2026, BVF Partners L.P. directly sold 3,750,000 shares of common stock for approximately $62.96 million, indicating ongoing interest in MoonLake Immunotherapeutics despite the sale.
- Historical Comparison: This transaction marks the largest direct sale reported by BVF in the SEC database, surpassing the previous sale of 2,000,000 shares, suggesting a strategic adjustment in their investment approach towards MoonLake.
- Holding Analysis: Post-transaction, BVF retains 15.9 million shares and an additional 25,667 shares via unexercised options, indicating a willingness to participate in future price appreciation, even after trimming its holdings.
- Investor Outlook: Although BVF reduced its stake by 19%, it still represents 8.76% of its total AUM, reflecting continued confidence in MoonLake's long-term growth potential, particularly with its proprietary Nanobody technology targeting significant unmet medical needs.
BVF Sells 3.75 Million Shares of MoonLake Immunotherapeutics
- Sale Overview: On April 2, 2026, BVF Partners L.P. sold 3.75 million shares of MoonLake Immunotherapeutics for approximately $62.96 million, reducing its direct holdings to 1,039,238 shares, which represents a 78.30% decrease in ownership.
- Ownership Change: This transaction accounted for 78.30% of BVF's direct stake in MoonLake, indicating a strategic reduction in exposure to biotechnology investments rather than a complete exit, reflecting a cautious approach to market volatility.
- Company Strategy and Outlook: MoonLake focuses on leveraging its proprietary Nanobody technology to develop innovative therapies for inflammatory diseases, and despite BVF's sale, the company continues to advance its pipeline targeting dermatological and rheumatological conditions, suggesting potential for long-term growth.
- Market Reaction and Investment Advice: Although MoonLake's shares have rebounded sharply since the beginning of the year, the high volatility in the biotechnology sector necessitates caution from investors; BVF's sale appears more as a portfolio rebalancing move rather than a negative outlook on the company's future prospects.
MoonLake's Clinical Trial Results Spark Interest
- Clinical Trial Results: MoonLake recently announced that in its late-stage trials, 62% of patients treated with sonelokimab achieved a 75% reduction in abscess and inflammatory nodule count, setting a new standard for long-term control of HS, surpassing existing FDA-approved drugs.
- Positive Market Reaction: Following the clinical data release, MoonLake's stock garnered significant retail interest on Stocktwits, with sentiment remaining in the 'extremely bullish' territory, indicating strong confidence in the company's future performance.
- Optimistic Analyst Ratings: According to Koyfin, 12 out of 16 analysts covering MLTX rated it 'Buy' or higher, with an average 12-month price target of $26.71, suggesting a potential upside of about 41%, reflecting market expectations for long-term growth.
- Acquisition Rumors Resurface: Despite Merck's failed attempt to acquire MoonLake for over $3 billion, optimism regarding potential future buyouts remains strong among investors, driven by interest in recent mergers in the biopharma sector, which could further boost the stock price.
MoonLake Immunotherapeutics Phase 3 Trial Results Show Promising Outcomes
- Sustained Clinical Improvement: In the Phase 3 VELA trials, 62% of patients achieved HiSCR75 by Week 40, indicating significant clinical responses and reinforcing Sonelokimab's potential for long-term disease control, addressing a critical unmet need for patients and physicians.
- Quality of Life Enhancement: Patients experienced an average HiSQOL score improvement of 12 points, with most transitioning from 'very severe' to 'mild/none', which not only enhances patient quality of life but also provides a positive outlook for future treatment options.
- Significant Pain Relief: Up to 43% of patients achieved at least a 3-point improvement in worst skin pain, demonstrating Sonelokimab's effectiveness in alleviating patient suffering, potentially attracting more patients for subsequent treatments.
- Good Safety Profile: No new safety signals were observed throughout the trials, and discontinuation rates remained low, establishing a solid foundation for Sonelokimab's market launch and future BLA submission.
Escalating Middle East Tensions Impact Markets
- Escalating Middle East Conflict: The conflict in the Middle East has entered its fifth week with the involvement of Houthi militants and the deployment of 3,500 additional U.S. troops, raising fears of broader escalation, which has led the Dow to enter correction territory and the S&P 500 to post its fifth consecutive weekly decline, indicating cautious investor sentiment.
- Oil Price Surge Risk: Brent crude prices surged above $116 in early Monday trading, with analysts warning that if the conflict extends through June, oil could reach $200 per barrel, highlighting the potential threat to global energy supplies stemming from the escalating tensions in the region.
- Market Reaction: Despite President Trump's extension of the deadline for potential strikes on Iran's energy infrastructure, investor sentiment remains cautious, resulting in S&P 500 and Nasdaq 100 futures declining by 0.6% and 0.7% respectively, reflecting the market's heightened sensitivity to geopolitical risks.
- Gold Market Turmoil: Global long-term bonds experienced $4.7 billion in weekly outflows, while gold prices approached $4,490, indicating a rising demand for safe-haven assets, with 95% of stocks in the VanEck Gold Miners ETF now in a bear market, reflecting market uncertainty and investor risk aversion.
MLTX Stock Soars After Positive Phase 3 Results for Lead Skin Disease Treatment, Most Patients Show Improvement
Treatment Efficacy: Recent data from the Week-40 Phase 3 trials indicate that 62% of patients treated with Sonelokimab for hidradenitis suppurativa showed significant improvement after 40 weeks, with up to 32% achieving near-complete lesion clearance.
Patient Outcomes: Patients reported reductions in pain and improvements in daily functioning, with 65% experiencing overall quality of life enhancements and 43% noting a clear reduction in their worst skin pain.
Market Response: Shares of Moon Lake Immunotherapeutics (MLTX) rose over 6% following the positive trial results, reflecting strong investor sentiment and expectations for continued clinical benefits.
Future Developments: The company is preparing for upcoming trials and potential regulatory submissions, with a focus on expanding its treatment options and maintaining a consistent safety profile as indicated by previous studies.
